Bruna de Moraes Mazetto Fonseca

Bruna de Moraes Mazetto Fonseca

Auto-generated profile, based on publicly available information

Bruna de Moraes Mazetto Fonseca

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2014 in Thrombosis Research
Verified
Journal Article
Closed access
PDF file
LBLuis Fernando Bittar
Luis Fernando Bittar
BMBruna de Moraes Mazetto
Bruna de Moraes Mazetto
FOFernanda A. Orsi
Fernanda A. Orsi
MCMarina P. Collela
Marina P. Collela
EPErich Vinícius De Paula
Erich Vinícius De Paula
JAJoyce Maria Annichino-Bizzacchi
Joyce Maria Annichino-Bizzacchi

21 March 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SNSomanathapura K. NaveenKumar
Somanathapura K. NaveenKumar
ATAjay Tambralli
Ajay Tambralli
BFBruna Mazetto Fonseca
Bruna Mazetto Fonseca
SYSrilakshmi Yalavarthi
Srilakshmi Yalavarthi
WLWenying Liang
Wenying Liang
JKJason Knight
Jason Knight
Many patients with antiphospholipid syndrome had decreased ectonucleotidase activity on neutrophils and platelets, which enabled extracellular nucleotides to trigger neutrophil-platelet aggregates. This phenotype was replicated by treating healthy neutrophils and platelets with patient-derived antiphospholipid antibodies or ectonucleotidase inhibitors.


25 May 2022 in Lupus
Verified
Journal Article
Closed access
ASAna Paula Rosa dos Santos
Ana Paula Rosa dos Santos
CVCamila de Oliveira Vaz
Camila de Oliveira Vaz
BHBidossessi Wilfried Hounkpe
Bidossessi Wilfried Hounkpe
BJBruna Cardoso Jacintho
Bruna Cardoso Jacintho
JOJosé Diogo Oliveira
José Diogo Oliveira
FOFernanda A. Orsi
Fernanda A. Orsi
Background: Thrombotic risk in antiphospholipid syndrome (APS) is conferred by the association of antiphospholipid (aPL) antibodies (first hit) with additional pro-coagulant stimulus (second hit), such as inflammation. Among inflammatory responses, the production of large amounts of interferon (IFN)-I by plasmacytoid dendritic cells (pDCs) is at the basis of the pathophysiology of systemic autoimmune disorders, which raises the hypothesis that this mechanism could also be associated with vascular manifestations of APS. Purpose: Here, we determined the association of pDCs and IFN-I production with thrombotic APS. Research design: Patients with thrombotic primary (t-PAPS) and secondary APS (t-SAPS), asymptomatic aPL carriers and individuals without thrombosis (controls) were included. Data collection and analysis: Circulating pDCs and IFN-α intracellular expression (in the presence or not of oligodeoxynucleotides (CP) stimulus) were quantified by flow cytometry. The expression of five IFN-I inducing genes: ISG15, OASL, Ly6E, MX1, and OAS1 in mononuclear cells was determined by qPCR. Between-group differences were evaluated using chi-square or Kruskal–Wallis tests. Results: A total of 50 patients with t-PAPS, 50 patients with t-SAPS, 20 aPL carriers, and 50 individuals without thrombosis (controls) were included. Intracellular expression of IFN-α was increased after CPG stimulation in both t-SAPS (1.56%; IQR 1.07–2.02) and t-PAPS (0.96%; IQR 0.55–1.24), when compared to aPL carriers (0.71%; IQR 0.42–0.93) and controls (0.48%; IQR 0.24–0.78; p < .0001). ISG15, OASL, Ly6E, MX1, and OAS1 mRNA expressions were higher in t-SAPS (but not in t-PAPS) than in aPL carriers and controls. The expression of proteins and mRNA related to IFN-I response was similar between the triple aPL-positive profile and other aPL profiles. Conclusion: Our results indicate an association of IFN-I response and t-APS. Since IFN-I expression was not increased in aPL carriers or associated with a higher-risk aPL profile, this mechanism does not appear to be related to the presence of aPL alone. IFN-I response could possibly constitute a complementary mechanism for triggering clinical manifestations in APS.

29 October 2025 in Blood Advances
Verified
Journal Article
Open access
SNSomanathapura K. NaveenKumar
Somanathapura K. NaveenKumar
TNThalia G. Newman
Thalia G. Newman
BFBruna Mazetto Fonseca
Bruna Mazetto Fonseca
SYSrilakshmi Yalavarthi
Srilakshmi Yalavarthi
MNMariane C. Flores Nascimento
Mariane C. Flores Nascimento
JKJason Knight
Jason Knight
Platelet activation is a hallmark of antiphospholipid syndrome (APS). However, the mechanisms through which antiphospholipid antibodies activate platelets and the optimal way to inhibit this pathophysiology are still not fully understood. Extracellular adenosine, produced by the ectoenzyme CD73, activates cell-surface receptors to increase intracellular cyclic adenosine monophosphate (cAMP), raising the threshold for platelet activation. Here, we found that platelets from patients with APS exhibited lower CD73 activity and cAMP content than healthy controls. Platelet activation, as measured by the surface expression of CD62P and activated αIIbβ3, was negatively correlated with CD73 activity and cAMP content. Exposing healthy platelets to APS patient immunoglobulin G (IgG) in vitro significantly reduced CD73 activity and intracellular cAMP while simultaneously increasing activation markers. We identified critical roles for FcγRIIa, phospholipase C, and the Akt signaling pathway in platelet activation by APS IgG. We also tested whether various agents that boost intracellular cAMP could blunt APS IgG–induced platelet activation. Agonism of the adenosine 2A receptor (A2AR) and inhibition of phosphodiesterase 3 (PDE3) were both highly effective in this regard. In summary, a dysregulated adenosinergic axis appears to potentiate APS platelets for prothrombotic activation by antiphospholipid antibodies. A2AR agonists and PDE3 inhibitors may be useful strategies for restoring platelet homeostasis in APS.

29 October 2024 in Journal of Sustainability Perspectives
Verified
Journal Article
Open access
PDF file
MMMayara Melo
Mayara Melo
CCCarla Cavaliero
Carla Cavaliero
BMBruna Moraes
Bruna Moraes
TDThalita Dalbelo
Thalita Dalbelo
Since 2019, the State University of Campinas (UNICAMP) has been collecting data, preparing, and annually monitoring sustainability indicators submitted to the UI GreenMetric ranking, which guide improvement projects at the university in alignment with the Sustainable Development Goals (SDGs). This article aims to propose sustainable practices for managing urban mobility on its campuses, drawing inspiration from the experiences of national and international universities that ranked highest in the 2023 edition of the aforementioned ranking. The study employed both qualitative and quantitative research methods, using a descriptive approach combined with Deductive Content Analysis (DCA). This analysis was further validated by the Multi-Criteria Decision-Making (MCDM) method known as Fuzzy SWARA. Through this process, the study identified the most commonly adopted actions by universities: promoting the use of electric and/or conventional bicycles on campus (11.8%); projects in partnership with government, state, or municipal entities to develop express cycle paths and encourage bicycle use both on campus and in the city (9.2%); conventional bicycle rental on campus (9.2%); and electric car sharing on campus (9.2%). The proposals suggested for UNICAMP include encouraging carpooling, implementing a public transportation exemption or half-fare program for employees, promoting the use of bicycles while ensuring increased campus security, among other initiatives. This research is part of a proposal for a Climate Action Plan for the university, which aims to effectively integrate sustainability into the university's agenda and support the fight against the climate emergency through necessary adaptations.